Keryx Presents Early Results Perifosine Trial

Keryx Biopharmaceuticals reported early results of a Phase II single-agent trial of perifosine in patients with recurrent malignant glioblastoma and anaplastic gliomas.

Twenty-five patients were treated with a loading dose of 600 mg followed by a 100-mg dose of perifosine.

The median progression-free survival and overall survival in the anaplastic glioma group was nine weeks and 49 weeks, respectively. The anaplastic glioma arm will continue enrollment because at least one patient achieved six months of progression-free survival, Keryx said.